A detailed history of Farallon Capital Management LLC transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Farallon Capital Management LLC holds 17,000 shares of COGT stock, worth $133,620. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,000
Previous 425,161 96.0%
Holding current value
$133,620
Previous $3.58 Million 94.89%
% of portfolio
0.0%
Previous 0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.24 - $11.48 $3.36 Million - $4.69 Million
-408,161 Reduced 96.0%
17,000 $183,000
Q2 2024

Aug 14, 2024

SELL
$6.01 - $9.04 $221,402 - $333,024
-36,839 Reduced 7.97%
425,161 $3.58 Million
Q1 2024

May 15, 2024

BUY
$4.38 - $9.02 $1.95 Million - $4.01 Million
445,000 Added 2617.65%
462,000 $3.1 Million
Q4 2023

Feb 14, 2024

BUY
$4.06 - $10.08 $69,020 - $171,360
17,000 New
17,000 $99,000
Q3 2023

Nov 14, 2023

BUY
$9.69 - $13.34 $164,730 - $226,780
17,000 New
17,000 $165,000
Q1 2023

May 15, 2023

BUY
$10.04 - $15.5 $9.02 Million - $13.9 Million
898,313 Added 1055.11%
983,452 $10.6 Million
Q4 2022

Feb 14, 2023

SELL
$10.65 - $14.84 $1.7 Million - $2.37 Million
-160,000 Reduced 65.27%
85,139 $984,000
Q3 2022

Nov 14, 2022

SELL
$9.39 - $16.99 $7.09 Million - $12.8 Million
-754,861 Reduced 75.49%
245,139 $3.66 Million
Q2 2022

Aug 15, 2022

BUY
$3.92 - $9.73 $588,000 - $1.46 Million
150,000 Added 17.65%
1,000,000 $9.02 Million
Q1 2022

May 16, 2022

BUY
$5.31 - $8.7 $1.33 Million - $2.18 Million
250,000 Added 41.67%
850,000 $6.37 Million
Q4 2020

Feb 16, 2021

BUY
$9.04 - $13.01 $5.42 Million - $7.81 Million
600,000 New
600,000 $6.74 Million

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $517M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track This Portfolio

Track Farallon Capital Management LLC Portfolio

Follow Farallon Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farallon Capital Management LLC with notifications on news.